Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

is small and the rate of severe muscle adverse effects (rhabdomyolysis) because of statins is extremely low. [May 2023] Discuss possible interactions between statins and other substances 1.5.4 Advise people who are being treated with a statin: • that other drugs, some foods (for example, grapefruit juice) and some supplements may interfere with statins and • to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements. [May 2023] Perform baseline blood tests and clinical assessment 1.5.5 Before starting statins perform baseline blood tests and clinical assessment. Include all of the following in the assessment: • smoking status • alcohol consumption • blood pressure (see NICE's guideline on hypertension in adults) • BMI or other measure of obesity (see NICE's guideline on overweight and obesity management) • full lipid profile • diabetes status • renal function • transaminase level (alanine aminotransferase or aspartate aminotransferase) • thyroid-stimulating hormone level in people with symptoms of underactive or overactive thyroid. [May 2023, amended December 2023] 1.5.6 Do not routinely exclude from statin treatment people who have liver transaminase levels that are raised but are less than 3 times the upper limit of
